As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current statutory profit is not always a good guide to a company’s underlying profitability. In this article, we’ll look at how useful this year’s statutory profit is, when analysing Boryung Pharmaceutical (KRX:003850).
It’s good to see that over the last twelve months Boryung Pharmaceutical made a profit of ₩27.7b on revenue of ₩562.4b. The chart below shows that revenue has improved over the last three years, and, even better, the company has moved from unprofitable to profitable.
Check out our latest analysis for Boryung Pharmaceutical
Of course, it is only sensible to look beyond the statutory profits and question how well those numbers represent the sustainable earnings power of the business. In this article we will consider how Boryung Pharmaceutical’s decision to issue new shares in the company has impacted returns to shareholders. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
To understand the value of a company’s earnings growth, it is imperative to consider any dilution of shareholders’ interests. Boryung Pharmaceutical expanded the number of shares on issue by 8.1% over the last year. As a result, its net income is now split between a greater number of shares. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. Check out Boryung Pharmaceutical’s historical EPS growth by clicking on this link.
A Look At The Impact Of Boryung Pharmaceutical’s Dilution on Its Earnings Per Share (EPS).
Three years ago, Boryung Pharmaceutical lost money. And even focusing only on the last twelve months, we see profit is down 16%. Sadly, earnings per share fell further, down a full 18% in that time. So you can see that the dilution has had a bit of an impact on shareholders. Therefore, the dilution is having a noteworthy influence on shareholder returns. And so, you can see quite clearly that dilution is influencing shareholder earnings.
In the long term, if Boryung Pharmaceutical’s earnings per share can increase, then the share price should too. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company’s share price might grow.
Our Take On Boryung Pharmaceutical’s Profit Performance
Over the last year Boryung Pharmaceutical issued new shares and so, there’s a noteworthy divergence between EPS and net income growth. Because of this, we think that it may be that Boryung Pharmaceutical’s statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. At the end of the day, it’s essential to consider more than just the factors above, if you want to understand the company properly. If you want to do dive deeper into Boryung Pharmaceutical, you’d also look into what risks it is currently facing. For example – Boryung Pharmaceutical has 3 warning signs we think you should be aware of.
Today we’ve zoomed in on a single data point to better understand the nature of Boryung Pharmaceutical’s profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
Promoted
When trading Boryung Pharmaceutical or any other investment, use the platform considered by many to be the Professional’s Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
